Don Dizon, MD
Enriched profileSystem Chief of Hematology-Oncology, Tufts Medicine; Jane F. Desforges Endowed Chair in Hematology and Oncology and Professor of Medicine, Tufts University School of Medicine · Tufts Medicine
Don Dizon is System Chief of Hematology-Oncology, Tufts Medicine; Jane F. Desforges Endowed Chair in Hematology and Oncology and Professor of Medicine, Tufts University School of Medicine at Tufts Medicine. OpenAlex indexes 509 publications with 11,747 citations (h-index 58); ClinicalTrials.gov lists 20 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 1 Sept 2026
Don S. Dizon, MD, is System Chief of Hematology-Oncology, Tufts Medicine. The public record shows 509 publications with 11,747 citations (h-index 58), centered on Breast Cancer, Ovarian / Gynecologic Cancer, Prostate Cancer. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2020–2020).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Breast Cancer
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Editor
CA: A Cancer Journal for Clinicians (American Cancer Society flagship journal), effective April 1
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pressroom.cancer.org ↗ - Vice Chair of Membership and Accrual
SWOG Cancer Research Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tuftsmedicine.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer
Sponsor: Tufts Medical Center
- E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Industry payments
Updated 1 Sept 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- TerSera Therapeutics LLCProgram year20257 payments
- Stemline Therapeutics Inc.Program year20251 payment
- AstraZeneca UK LimitedProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.3%Poly(ADP-Ribose) Polymerase Inhibitor23.7%Lynparza63%Zejula38%Part D<11 patientsEstrogen Agonist/Antagonist9.6%Tamoxifen Citrate100%Part D<11 patientsMetabolism & gastrointestinal
27.4%Serotonin-3 Receptor Antagonist27.4%Ondansetron Hcl100%Part D≥28 patientsNervous system
20.7%Phenothiazine20.7%Prochlorperazine Maleate100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
1 NIH research award on record, funded 2020–2020 per NIH RePORTER. The latest:
- The Collaboration for Outcomes using Social Media in Oncology (COSMO) Conference
Rhode Island Hospital
FY2020$10,000R13CA239613
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition.
Journal of clinical oncology
Article2026 - Staff Perspectives on Normalizing and Sustaining Electronic Patient-Reported Outcomes Monitoring at Six US Health Systems.
JCO oncology practice
Article2026 - CA turns 75: Looking at the future but never forgetting the roots.
CA: a cancer journal for clinicians
Editorial2025
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Facebook
facebook.com/drdonstevendizon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/drdonsdizon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/in/donsdizonmd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-120
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Tiktok.com
TikTok: @drdonsdizon ("DoctorDon"), oncology and social-media-in-medicine commentary
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tiktok.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vivo.brown.edu ↗
Editorial & leadership roles
journal and society appointments- System Chief of Hematology-Oncology
Tufts Medicine cancer service line
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - Jane F. Desforges
MD, Endowed Chair in Hematology and Oncology, Tufts University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Professor of Medicine
Tufts University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tuftsmedicine.org ↗
Awards & honors
honors on the public record- Excellence in Equity Award
American Society of Clinical Oncology (endowed by the American Cancer Society), 2025 ASCO Annual Meeting
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
Secondary affiliations
appointments beyond the home institution- Formerly Professor of Medicine and Professor of Surgery
Warren Alpert Medical School of Brown University; Lifespan Cancer Institute / Legorreta Cancer Center, Providence, RI
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brownhealth.org ↗
Media & interviews
press, podcasts and appearances- Video commentary
"Don S. Dizon on Ovarian and Other Extrarenal Clear Cell Carcinomas Update on Nivolumab and Ipilimumab," The ASCO Post
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Host
"Your Stories: Conquering Cancer" podcast, Conquer Cancer (the ASCO Foundation)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →conquer.org ↗ - "Get to Know Don S. Dizon, MD, FACP, FASCO, System Chief of Hematology-Oncology"
Tufts Medicine video feature
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles